PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.

Arch Med Sci · 2017 · PMC5510512 · PMID 28721159

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Anti-PCSK9 antibodies reduced the incidence of all-cause mortality (OR = 0.43; 95% CI: 0.22–0.82; p = 0.01), whereas the change in risk of cardiovascular death (OR = 0.50; 95% CI: 0.22–1.13; p = 0.10) and cardiovascular events (OR = 0.67; 95% CI: 0.43–1.04; p = 0.07) did not reach statistical significance [ 93 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.